Accelerating biosimilar market access: the case for allowing earlier standing.

Area of Science:

• Pharmaceutical Sciences
• Health Economics
• Intellectual Property Law

Background:

• Biosimilars offer affordable alternatives to biologic medicines.
• Current patent litigation frameworks delay biosimilar market entry.
• Generic drug litigation has fewer pre-launch restrictions.

Purpose of the Study:

• To analyze current patent litigation challenges for biosimilars.
• To propose reforms to expedite biosimilar market entry.
• To reduce delays in accessing affordable biologic medicines.

Main Methods:

• Examination of the Biologic Price Competition and Innovation Act's patent litigation provisions.
• Comparison of biosimilar and generic drug litigation timelines.
• Analysis of proposed reforms for earlier litigation initiation.

Main Results:

• Biosimilar litigation can only begin after FDA application submission, post-clinical trials.
• This timing creates significant market entry delays compared to generics.
• Proposed reform could reduce delays by approximately 1.8 years.

Conclusions:

• The current patent litigation framework hinders biosimilar market access.
• Initiating biosimilar litigation at the start of phase 3 trials is recommended.
• Litigation reform can accelerate the availability of affordable biosimilars.